Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05715528 · ClinicalTrials.gov registry record · Phase 3
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,011
- Enrollment target
NCT05715528 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 2,011 participants.
The verdict
NCT05715528, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,011 participants
- Enrollment target
Study Summary
The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
Interventions
- DRUG Obeldesivir
- DRUG Obeldesivir Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,011 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05715528
The ClinicalTrials.gov registry entry for NCT05715528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,011 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obeldesivir is the first listed.
NCT05715528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05715528 about?
NCT05715528 is a clinical study titled "Study of Obeldesivir in Nonhospitalized Participants With COVID-19". The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long...
What is the current status of trial NCT05715528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,011 participants. The study started on 2023-02-08. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT05715528?
The interventions under investigation include: Obeldesivir (DRUG), Obeldesivir Placebo (DRUG).
Who is sponsoring clinical trial NCT05715528?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.